A therapy for celiac disease is one step closer. ImmunogenX purchased the license for Alvine Pharmaceuticals’ medicine, ALV003, which degrades gluten before it can be digested and absorbed by the intestines. The following press release was distributed by ImmunogenX.
“Glutenase for in-vivo gluten degradation is a leading candidate for celiac disease ImmunogenX™, a biopharmaceutical company focused on the diagnosis and treatment of autoimmune and gastrointestinal diseases, today announced that it has completed the acquisition of the non-cash assets of Alvine Pharmaceuticals.
This includes Latiglutenase (formerly known as ALV003 and renamed IMGX003), an orally administered mixture of two recombinant gluten-specific proteases that degrades gluten proteins into small physiologically irrelevant fragments. The technology is backed by over 50 issued or pending patents, has been extensively studied in Phase I and Phase 2 clinical trials, and is the only CD treatment that has demonstrated histologic success as well as symptomatic improvements in Read More »